DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Sebi updates audit committee norms for MIIs
20/05/2025
RBI accepts lower bond purchase amount in first FY26 OMO auction
20/05/2025
Protean eGov Technologies shares plunge 20% after downgrade amid PAN 2.0 project withdrawal
20/05/2025
How will Resonac's plant closures impact the global graphite market ?
20/05/2025
RBI okays Emirates NBD Bank PJSC's subsidiary plan in India
19/05/2025
The UK and the EU announce new deals and renew ties, 5 years after Brexit
19/05/2025
